Study objective: Induction doses of etomidate during rapid sequence intubation cause transient adrenal dysfunction, but its clinical significance on trauma patients is uncertain. Ketamine has emerged as an alternative for rapid sequence intubation induction. Among adult trauma patients intubated in the emergency department, we compare clinical outcomes among those induced with etomidate and ketamine.
INTRODUCTION Background
Trauma is the leading cause of death for Americans younger than 45 years and accounts for 30 million emergency department (ED) visits and 3 million hospitalizations annually in the United States.
1,2 Clinical practice guidelines recommend rapid sequence intubation as the procedure of choice for intubating acutely injured patients. 3 Because of their rapid onset and favorable hemodynamic effects, both etomidate and ketamine are used for rapid sequence intubation induction in trauma. [4] [5] [6] [7] [8] [9] [10] However, whether one agent should be preferred over the other for rapid sequence intubation of trauma patients remains unclear.
Importance
Induction doses of etomidate inhibit the 11-ß hydroxylase enzyme and cause transient adrenal suppression that may negatively affect severely injured patients. [11] [12] [13] [14] [15] [16] Although ketamine has emerged as an alternative to etomidate for rapid sequence intubation in trauma, experience with it in this setting is limited because of historical concerns about it increasing intracranial pressure and evidence suggesting it has a direct myocardial depressant
Editor's Capsule Summary
What is already known on this topic Concerns about etomidate-associated adrenal suppression have led some emergency physicians to substitute ketamine as their rapid sequence induction agent.
What question this study addressed Do mortality and morbidity after trauma intubation differ between etomidate and ketamine?
What this study adds to our knowledge In this before-and-after study of 968 adults, mortality, ICU-free days, and ventilator-free days were similar between groups.
How this is relevant to clinical practice
In the setting of trauma, etomidate-associated adrenal suppression is not clinically important.
effect, which may lead to complications in critically ill patients with diminished physiologic reserve.
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Goals of This Investigation
In response to early data suggesting etomidate-induced adrenal dysfunction may be associated with adverse outcomes in trauma, [22] [23] [24] [25] in December 2012 our institution changed the standard induction agent for ED rapid sequence intubation of trauma patients from etomidate to ketamine. Using this systematic protocol change, we compared the morbidity and mortality of trauma patients intubated with etomidate and ketamine during a 4-year period spanning this practice change.
MATERIALS AND METHODS Study Design and Setting
This was a retrospective analysis of data collected at an academic, tertiary care, Level I trauma center in the United States, with approximately 70,000 adult ED visits and 3,600 acute trauma admissions annually. The study period was January 1, 2011, through December 31, 2014. Adult trauma patients were intubated by emergency physicians using a standardized clinical protocol. Before December 2012, etomidate was the on-protocol, standard induction agent for ED rapid sequence intubation of trauma patients. In December 2012, ketamine replaced etomidate as the onprotocol induction agent. There were no other changes to the rapid sequence intubation protocol during this time. Recommended induction doses were etomidate 0.3 mg/kg and ketamine 1 to 2 mg/kg. Succinylcholine was the standard on-protocol rapid sequence intubation paralytic throughout the study period. All treatment decisions were made by treating clinicians independent of this study; throughout the study period, treating clinicians had the ability to select an off-protocol induction agent according to clinical discretion. The study was approved by the local institutional review board with waiver of informed consent.
Selection of Participants
Patients aged 18 years or older were included if they presented with acute trauma and were intubated in the ED with either etomidate or ketamine for rapid sequence intubation induction. Several a priori subgroups were also identified, including patients with traumatic brain injury; Glasgow Coma Scale (GCS) score less than 15 at presentation; penetrating trauma; "major trauma," defined as an Injury Severity Score (ISS) greater than 15; and systolic blood pressure less than 100 mm Hg at presentation. These subgroups were selected according to the hypothesis that patients with traumatic brain injury and severe trauma may be particularly vulnerable to etomidate-induced adrenal suppression. 26, 27 Traumatic brain injury was defined as intracranial hemorrhage, diffuse axonal injury, or shear injury identified by an attending radiologist on the first head computed tomography (CT) scan after presentation.
As detailed in the "Data Analysis" section below, 2 separate analyses were conducted and the exposure definitions varied per analysis. In the primary analysis, patients who received ketamine were compared with those who received etomidate, regardless of which anesthetic was the on-protocol induction agent at the time. A secondary, quasi-experimental analysis assessed the effect of the rapid sequence intubation protocol change from etomidate to ketamine; for this analysis, outcomes from patients intubated after the induction agent protocol switch in December 2012 (the ketamine period) were compared with those intubated before the protocol switch (the etomidate period), regardless of the induction agent received.
Outcome Measures
The primary outcome was hospital mortality, defined as death in the ED or during the index hospitalization after rapid sequence intubation in the ED. Secondary outcomes included days alive and outside an ICU between ED rapid sequence intubation and 28 days later (ICU-free days); days alive and free of invasive mechanical ventilation between ED rapid sequence intubation and 28 days later (ventilatorfree days); days alive and free of vasopressor support between ED rapid sequence intubation and 28 days later (vasopressor-free days); units of packed RBCs transfused in the first 48 hours; hospital-acquired sepsis to day 28, defined as greater than or equal to 2 systemic inflammatory response syndrome criteria with confirmed or suspected source of infection; time to hospital discharge; and hazard of hospital death. Consistent with data from previous literature on the "free day" composite outcomes, 28 patients who died before day 28 were considered to have experienced zero ICU-free days, ventilator-free days, and vasopressor-free days, and those discharged or transferred before day 28 were assumed to have no additional days in the ICU, days receiving ventilator support, or days receiving vasopressors after discharge or transfer.
Additional outcomes used to assess intubating conditions during rapid sequence intubation included first-pass intubation success, need for rescue surgical airway, and peri-intubation cardiac arrest, defined as cardiac arrest within 1 hour of induction agent administration.
Data Collection and Processing
Data were abstracted from the electronic medical record, our medical center enterprise data warehouse, and the institution's Trauma Registry of the American College of Surgeons database. Data were collected with high-quality chart review standards 29 and managed with the REDCap (Vanderbilt, Nashville, TN) electronic data capture tool. 30 After case identification and extraction from our data registries, medical record data were collected by a single investigator (C.P.U.), who was a senior medical student trained on the study protocol and variable definitions by the senior investigator. A second investigator (W.H.S.) independently reviewed a random 10% subset of included patients, and interrater agreement between the 2 reviewers was calculated for the primary exposure variable (induction agent) and the primary outcome (hospital mortality). Chart abstractors were not blinded to the study's purpose.
Data Analysis
For the primary analysis, exposure groups were defined by the induction agent administered to each patient. Multivariable logistic regression models were used to evaluate the association between induction agent (ketamine versus etomidate as a referent) and hospital mortality. Model covariates, selected a priori according to literature review 31, 32 and mechanistic plausibility for confounding, included age; sex; ED presentation pulse rate, systolic blood pressure, and GCS score; ISS; and injury mechanism (blunt versus penetrating). Age, pulse rate, and systolic blood pressure had nonlinear relationships with mortality and were modeled with 4-knot restricted cubic spline functions. 33 The association between induction agent and hospital mortality was also estimated for each subgroup with this model. For these subgroup analyses, interaction terms between the subgroup and induction agent were examined, and estimates of association between induction agent and hospital mortality were calculated with linear combinations of coefficients from the regression models that included the interaction terms. 34 Multivariable models for secondary outcomes were constructed with the same covariates used in the mortality model. ICU-free days, ventilator-free days, vasopressor-free days, and units of packed RBCs transfused were modeled with ordered logistic regression. Hospital-acquired sepsis was modeled with logistic regression. Time to hospital discharge was modeled with proportional hazard regression while considering hospital death as a competing risk event.
Hazard of hospital death was modeled with proportional hazard regression, with hospital discharge treated as a censoring event.
In a secondary analysis, the association between the implementation of ketamine as the new on-protocol induction agent for ED rapid sequence intubation of trauma patients and hospital mortality was evaluated with an interrupted time series analysis. 35, 36 The 4-year study period was divided into 24 two-month intervals (bimonths). The etomidate period (before the institutional protocol switch) was defined as January 2011 to October 2012 (11 bimonths). November 2012 to February 2013 (2 bimonths) was defined as a transition period as the protocol change was introduced and implemented and was excluded from analysis. The ketamine period (after the institutional protocol switch) was defined as March 2013 to December 2014 (11 bimonths). A segmented linear regression model was constructed to analyze changes in hospital mortality over time. 37 The dependent variable for the model was the proportion of patients who died (hospital mortality) during each bimonthly interval. Independent variables included a term for the time of protocol change from etomidate to ketamine and terms for secular trends in the etomidate and ketamine periods. Model output provided estimates for the change in hospital mortality over time during the etomidate and ketamine periods, as well as the immediate change in hospital mortality associated with the protocol switch.
Statistical analyses were conducted with Stata (version 12.1; StataCorp, College Station, TX) and R (version 3.2.3). We evaluated the overall calibration of our multivariable logistic regression model with the HosmerLemeshow goodness-of-fit test. Linear regression model assumptions were assessed through standard examination of residuals and evaluation of potential autocorrelation of error terms in our time-series data. These assessments indicated that our logistic regression model fit the data well, and no major departures from linear regression model assumptions were observed.
RESULTS
Characteristics of Study Subjects
The study population included 968 patients, including 526 (54%) who received etomidate and 442 (46%) who received ketamine (Figure 1) Table 2 ). This finding was consistent across all subgroups (Figure 2) .
Compared with etomidate, ketamine was associated with lower odds of hospital-acquired sepsis (adjusted OR 0.72; 95% CI 0.52 to 0.99) but fewer vasopressor-free days (adjusted OR 0.74; 95% CI 0.58 to 0.95), which corresponded to longer duration of vasopressor use. Otherwise, secondary outcomes were similar ( Table 2 and Figure E1 [available online at http://www.annemergmed.com]).
Peri-intubation outcomes were also similar in patients who received ketamine compared with those who received etomidate, including first-pass intubation success (93.7% versus 93.9%; absolute risk difference -0.2%; 95% CI -3.3% to 2.8%), need for rescue surgical airway (0.2% versus 0.2%; absolute risk difference 0; 95% CI -0.5% to 0.6%), and periintubation cardiac arrest (2.7% versus 1.5%; absolute risk difference 1.2%; 95% CI -0.8% to 3.0%). During the "etomidate period" before the institutional protocol switch from etomidate to ketamine, 508 patients were included in the study, including 466 (91.7%) who received etomidate and 42 (8.3%) who received ketamine ( Figure 3A) . During the transition period, there were 64 total patients, including 37 (57.8%) who received etomidate and 27 (42.2%) who received ketamine. During the "ketamine period" after the protocol switch, 396 patients were included in the study, including 362 (91.4%) who received ketamine and 34 (8.6%) who received etomidate ( Figure 3A) . ISS for included patients remained similar across the entire study period; the median ISS was 22 (IQR 13 to 34) during the etomidate period and 22 (IQR 13 to 29) during the ketamine period ( Figure 3A) . Patient characteristics were similar in the etomidate and ketamine periods (Table E1 , available online at http:// www.annemergmed.com).
Overall, unadjusted hospital mortality was 17.3% during the etomidate period and 20.7% during the ketamine period (absolute risk difference 3.4%; 95% CI -1.8% to 8.6%). In segmented regression analysis, there was no significant trend in hospital mortality during the etomidate period (-0.4% absolute change per bimonth; 95% CI -1.8% to 1.0%) and no significant change in hospital mortality immediately associated with the protocol switch from etomidate to ketamine (1.2% absolute change; 95% CI -11.3% to 13.6%). Furthermore, hospital mortality trends in the ketamine and etomidate periods did not significantly differ from one another (1.1% absolute change; 95% CI -0.8% to 3.1%) ( Figure 3B ). The segmented linear regression was repeated with adjustment for median ISS, and results were unchanged compared with those of the unadjusted analysis.
LIMITATIONS
Our study has some limitations. First, although several techniques were used to account for potential confounders, residual confounding was still possible.
Second, although our study is larger to our knowledge than all previously published studies comparing etomidate and ketamine for rapid sequence intubation in trauma, our sample size did not allow detection of small but potentially important differences in mortality. Duration of the study period was selected according to the timing of the rapid sequence intubation protocol switch from etomidate to ketamine at the study institution. We included patients intubated during the 2-year period before the protocol switch and the 2-year period afterward. This study duration was selected to balance considerations about sample size and practice variation over time that could confound the relationship between induction agent and hospital mortality. A longer study period would have resulted in a larger sample size but also potentially greater susceptibility to temporal variation in routine clinical practice administered to etomidate patients (predominantly treated in the early part of the study period) and ketamine patients (predominantly treated in the latter part of the study period).
Third, because of the nature of the protocol switch, our main analysis was based on nonconcurrent cohorts and was potentially susceptible to temporal changes in practice or patients. However, our groups were similar in measured NA, Not applicable *All models adjusted for age, sex, ED presentation pulse rate, systolic blood pressure, GCS score, ISS, and injury mechanism. Figure 2 . Association between induction agent received (ketamine versus etomidate) and hospital mortality by subgroup population. TBI, Traumatic brain injury; aOR, adjusted odds ratio. Adjusted for age, sex, ED presentation pulse rate, systolic blood pressure, GCS score, ISS, and injury mechanism.
characteristics, and differences were accounted for analytically. Furthermore, our secondary analysis with an interrupted time-series approach statistically adjusted for temporal trends in mortality.
Fourth, we did not directly measure adrenal function. However, it has been well established that induction doses of etomidate transiently impair cortisol synthesis [38] [39] [40] ; in the current study, we focused on evaluating whether ketamine was associated with an improvement in clinical outcomes compared with etomidate, with its known effect on adrenal function.
Fifth, full induction doses of etomidate (z0.3 mg/kg) and ketamine (1 to 2 mg/kg) were administered to nearly all patients in this study, and we were unable to assess whether lower doses would have led to better outcomes in hypotensive patients.
Sixth, our study was conducted at a single academic Level I trauma center, and further evaluation in other settings is indicated.
DISCUSSION
In this study of 968 adult trauma patients intubated at 1 institution during a 4-year period spanning an institutional protocol switch from etomidate to ketamine for ED rapid sequence intubation induction, use of ketamine compared with etomidate was not associated with an improvement in clinical outcomes, including hospital mortality, ICU-free days, ventilator-free days, vasopressor-free days, and transfusion requirements. Subgroup analyses of the most severely injured patients also consistently failed to show a mortality benefit for ketamine compared with etomidate.
The potential association between induction agent and hospital mortality was evaluated with 2 analyses: traditional multivariable regression techniques adjusting for potential patient-level confounders, and a quasi-experimental interrupted times-series analysis of the institutional protocol switch. These distinct but complementary analytical strategies led to similar conclusions: the use of ketamine was not associated with an improvement in hospital mortality compared with etomidate.
The National Emergency Airway Registry, a large multicenter surveillance group, demonstrated that etomidate was used in more than 90% of rapid sequence intubations in the ED during the last decade, whereas ketamine was used for only 1%. 41 However, the safety of etomidate has been repeatedly questioned because of the transient adrenal dysfunction it causes after induction. Several small studies have suggested it may be associated with poor outcomes in trauma patients. [22] [23] [24] [25] 42 Simultaneously, ketamine emerged as an attractive rapid sequence intubation induction agent because of new data showing it does not increase intracranial pressure in brain-injured patients 20, 21 and increased experience with its use for procedural sedation. Previous published data on the use of ketamine for rapid sequence intubation induction of trauma patients are limited. The KETASED trial, 43 in which critically ill adults undergoing rapid sequence intubation were randomized to etomidate or ketamine, included a subgroup of 104 trauma patients; there was a nonsignificant trend toward higher mortality in patients randomized to ketamine in this subgroup with trauma. Results of our study and the KETASED trial are similar and do not support concerns that etomidate-induced adrenal dysfunction is associated with worse patient-centered outcomes in trauma patients compared with ketamine.
In our study, ketamine was associated with lower odds of hospital-acquired sepsis compared with etomidate. Although this lower prevalence of infection did not translate into differences in mortality or duration of ICU or ventilator use, susceptibility to infection is a potential concern related to etomidate-associated adrenal dysfunction that will be important to evaluate in future trials. 25 Hospital-acquired sepsis was one of multiple secondary outcomes in our study, and this finding requires independent confirmation.
Ketamine was associated with fewer vasopressor-free days; that is, a longer duration of vasopressor use. Ketamine has indirect sympathomimetic effects by inhibiting reuptake of endogenous catecholamines, but also has direct myocardial depressant effects 17, 44 that may decrease ventricular contractility in critically ill patients. 19, 45 It has been proposed that the negative inotropic effects of ketamine may outweigh the sympathomimetic effects in patients with depleted physiologic reserve and potentially lead to increased mortality and longer duration of organ dysfunction in these patients. 18, 46 This finding also requires independent confirmation.
Because of the high volume of rapid sequence intubation procedures performed among trauma patients, even a small difference in mortality risk between induction agents could lead to substantial differences in survival on a population level. There is equipoise about the best rapid sequence intubation induction agent for trauma patients, and thus randomized controlled studies powered to detect relatively small but clinically important mortality differences are indicated. In the meantime, results from this quasiexperimental study can help inform clinical practice. Clinicians using etomidate for rapid sequence intubation of trauma patients should be reassured by the finding that ketamine was not associated with an improvement in mortality or other patient-centered outcomes in our study.
In conclusion, this study of 968 adult trauma patients who underwent ED rapid sequence intubation does not support the hypothesis that induction with ketamine is associated with more favorable patient-centered outcomes than etomidate. Figure E1 . Survival curves displaying the percentage of patients alive over time by induction agent received. Observation time was censored at hospital discharge. The aHR compares the hazard of death for patients who received ketamine with those who received etomidate (referent). Model covariates included age, sex, pulse rate, systolic blood pressure, GCS score, ISS, and injury mechanism. aHR, Adjusted hazard ratio. 
